Prostate Cancer and Apoptosis;Cáncer de próstata y apoptosis

Investigacion Clinica

Volumn 52, Issue 4, 2011, Pages 376-396

  Mayora, Adriana ^a   Arvelo, Francisco ^b,c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b Fundacion IDEA   (Venezuela)

^c FACULTAD DE CIENCIAS   (Venezuela)

Author keywords

Androgen; Apoptosis; Cancer; Hormone; Hormone resistant; Prostate

Indexed keywords

ANDROGEN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; GENE AMPLIFICATION; GENE MUTATION; MEDICAL LITERATURE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84859080133     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. Jemal A, Siegel R, Ward E, Murria T, Xu J, Smigal C. Cancer statistics. CA Cancer J Clin 2006; 56: 106-130.
2. Van Gils M, Stenman U, Schalken J, Schroder F, Luider T, Lilja H, Bjartell A, Hamdy F, Petterson K, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma C. Innovations in serum and urines markers in prostate cáncer current European research in the P-Mark Project. Eur Urol 2005; 48:1031-1041.
3. Sardana G, Dowell B, Diamandnis E. Emergig biomarkers for the diagnosis and prognosis of prostate cáncer. Clin Chem 2008; 54: 1951-1960.
4. ACC. Prostate Cancer: Risk factors and prevention 2006 (fram http://www.cancer.org)
5. Carter H, Piantadosi S, Isaacs J. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742-746.
6. Crawford E. Epidemiology of prostate cancer. Urology 2003;62: 3-12.
7. Capote Negrin L. Aspectos epidemiológicos del cáncer en Venezuela. Rev Venez Oncol 2006; 18: 269-281.
8. Mcdonnell T, Troncoso P, Brisbay S. Expression of the protooncogen bcl-2 in the prostate and its association with emergente of androgen-independent prostate cancer. Cancer Res 1992; 52: 6240-6244.
9. Reed J. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3: 17-22.
10. Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem 2008;104: 1124-1149.
11. Hentgarner M. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
12. Strasser A, ÓConnor L, Dixit V. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
13. Fulda S, Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
14. Hanahan D, Weinberg R. The hallmarks of cancer cell. Cell 2000; 100: 57-70.
15. Dehm S, Tindall D. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-334.
16. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 2003; 253: 89-101.
17. Navarro Bosch D, Cabrera Galvan J, Chesa Ponce N, Díaz Chico N. Prostate Cancer and androgen receptor gene. Rev Oncol 2002; 4: 228-240.
18. Avila D, Zoppi S, McPhaul M. The androgen receptor (AR) in síndromes of androgen insensitivity and in prostate cancer. J Steroid Biochem Mol Biol 2001; 76:135-142.
19. Mellado B, Codony J, Ribal M, Visa L, Gascón P. Molecular biology of androgen- independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 2009; 11: 5-10.
20. Culig Z, Hobisch A, Bartsch G. Androgen- receptor: An update of mechanisms of action in prostate cancer. Urol Res 2000; 28: 211-219.
21. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Belanger A. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000; 25: 1-16.
22. Mercader M, Sengupta S, Bodner B, Manecke R, Cosar E, Moser M, Ballman K, Wojcik E, Kwon E. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99: 60-67.
23. Feldman B, Feldman D. The development of androgen-independent. Nature 2001; 1: 35-45.
24. Cheng L, Bareman A, Assikis V, Zhau H. Molecular insights into prostate cancer progresión: the missing link of tumor microenvironment. J Urol 2005; 173: 10-20.
25. McKenzie S, Kyprianou N. Apoptosis evasión: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 2006; 97:18-32.
26. Zhu M, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-849.
27. Yeh S, Lin H, Kang H, Thin H, Lin M, Chang C. From HER2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96: 5458-5463.
28. Ansel P, Cyster J. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol 2001; 13: 172-179.
29. Culig Z, Bartsch G, Hobish A. Interleukin- 6 regulates androgen activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197: 231-238.
30. Ueda T, Bruchovsky N, Sadar M. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK y STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-7085.
31. Murata T, Noguchi P, Puri R. IL-13 induces phosphorylation and activation of JAK2 janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996; 156: 2972-2978.
32. Lee S, Lou W, Hou M, Onate S, Gao A. Interleukin 4 enhances prostate-nterleukin 4 enhances prostate specific antigen expresión by activation of the androgen receptor and Akt pathway. Oncogene 2003; 22: 7981-7988.
33. Walensky L. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13: 1339-1350.
34. Danial N. BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clin Cancer Res 2007; 13: 7254-7263.
35. Catz S, Johnson J. BCL-2 in prostate cáncer: a minireview. Apoptosis 2003; 8: 29-37.
36. McDonnell T, Troncoso P, Brisbay S, Logothetis C, Cheng L, Hsieh J, Tu S, Campbell J. Expression of the protooncogene bcl-2 in the prostate and its association with emergente of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
37. Pollack A, Cowen D, Troncoso P, Zagars G, von Eschenbach A, Meistrich M, McDonnell T. Molecular markers of outcome alter radiotherapy in patients with prostate carcinoma: Ki-67,bcl-2,bax and bcl-x. Cancer 2003; 97: 1630-1638.
38. Kim R, Emi M, Matsuura K, Tanabe K. Antisense and non-antisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 2007; 14: 1-11.
39. Castilla C, Congregado B, Chinchon D, Torrubia F, Japon M, Saez C. Bcl-xL is overexpressed in hormono-resistant prostate cancer and promotes survival of LNCap cells via interaction with proapoptotic Bak. Endocrinology 2006; 147: 4960-4967.
40. Lin Y, Kokontis J, Tang F, Godfrey B, Liao S, Lin A, Chen Y, Xiang J. Androgen and its receptor promote Bax mediated apoptosis. Mol Cell Biol 2006; 1908-1916.
41. Finnegan N, Curtin J, Prevost G, Morgan B, Cotter T. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interations. Br J Cancer 2001; 85: 115-121. sis. Nature 2006; 443: 658-662.
42. Zhou Z, Flesken-Nikitin A, Corney D, Wang W, Goodrich D, Roy-Burman P. Synergy of p53 and Rb deficiecy in a condicional mouse model for metastatic prostate cancer. Cancer Res 2006; 66: 7889-7898.
43. Smith A, Karpova Y, D'Agostino R, Willingham M, Kulik G. Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLos ONE 2009; 4: 1-6.
44. Eckelman B, Salvesen G. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006; 281: 3254-3260.
45. Rodriguez-Berriguete G, Fraile B, de Bethencourt F, Prieto-Folgado A, Bartolome N, Nuñez C, Prati B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. Role IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cáncer) human prostate. BMC Cancer 2010; 10: 18-23.
46. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi O, Shabaik A, Vitiello A, Peehl D, Gao G, Reed J. Elevated expresión on inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9: 4914-4925.
47. Gill C, Dowling C, O'Neill A, Watson R. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cáncer cell susceptibility to apoptosis cell survival and proliferation. Mol Cancer 2009; 8: 39-46.
48. McEleny K, Watson R, Coffey R, O'Nelly A, Fitzpatrick J. Inhibitors of apoptosis proteins in prostate cancer lines. Prostate 2002; 51: 133-140.
49. Zhang M, Mukherjee N, Bermudez R, Latham D, Delaney M, Zietman A, Shipley W, Chakravarti A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005; 64: 293-302.
50. Liu X, Gao R, Dong Y, Gao L, Zhao Y, Zhao L, Zhao X, Zhang H. Survivin gene silencing sensitizes prostate cancer cells to seleniun growth inhibition. BMC Cancer 2010; 10: 418-423.
51. Berezovskaya O, Schimmer A, Glinskii A, Pinilla C, Hoffman R, Reed J, Glinsky G. Increased expression apoptosis inhibitor protein XIAP contribuyes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005; 65: 2378-2386.
52. Fulda S, Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-47811.
53. Fulda S, Debatin K. Signaling through death receptors in cancer therapy. Curr Opin Pharmacol 2004; 4: 327-332.
54. Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L, Wang Y, Wang Z. The androgen receptor directly targerts the cellular Fas/FasL associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005; 19: 1792-1802.
55. Jiang J, Ulbright T, Zhang S, Eckert G, Kao C, Gardner T, Koch M, Eble J, Cheng I. Fas and Fas ligand expresión is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma Cancer 2002; 95: 296-300.
56. O'Kane H, Watson C, Johnston S, Petak I, Watson R. Targeting death receptors in bladder, prostate and renal cancer. J Urol 2006; 175: 432-438.
57. Hedlund T, Duke R, Schleicher M, Millar G. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998; 36: 92-101.
58. Van Horssen R, Ten Hagen T, Eggermont A. TNF-alpha in cancer treatment molecular insights effects and clinical utility. Oncologist 2006; 11: 397-408.
59. Chopra D, Menard R, Januszewski J, Mattingly R. TNF-alpha mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004; 203: 145-154.
60. Catz S, Johnson J. Transcriptional regulation of bcl-2 by factor kappa B and its significance in prostate cancer. Oncogene 2001; 20: 7342-7351.
61. Sarker D, Reid A, Yap T, de Bone J. Targeting the PI3K/ KT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
62. Wang S, El-Deiry W. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633.
63. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-237.
64. Shankar S, Chen X, Srivastava R. Effects of sequential treatments with chemotherapeutic durgs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005; 62: 165-186.
65. Walczak H. The CD95 (APO-1/Fas) and the trail (APO-2L) apoptosis systems. Exp Cell Res 2000; 256:58-66.
66. Rokhlin O, Guseva N, Tagiyev A, Knudson C, Cohen M. Bcl-2 oncoprotein protects the human prostatic carcinoma cell lin PC· from TRAIL-mediated apoptosis. Oncogene 2001; 20: 2836-2838
67. Volgeisten B, Lane D, Levine A. Surfing the p53 network. Nature 2000; 408: 307-310.
68. Ecke T, Schlechte H, Schiemenz K, Sachs M, Lenk S, Rudolph B, Loening T. TP53 gene mutations in prostate cancer mutations. Anticancer Res 2010; 30: 1579-1586.
69. Navone N, Troncoso P, Pisters L, Goodrow T, Palmer J, Nichols W, von Eschenbach A, Conti C. p53 accumulation and gene mutation in the progresión of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-1669.
70. Bray k, Chen H, Kanp C, May M, Ganesan S, Karantza-Wadsworth V, DiPaola R, White E. Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res 2009; 7: 1487-1496.
71. Borre M, Stausbol-Gon B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000; 164: 716-721.
72. Cronauer M, Schulz W, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004; 23: 3541-3549.
73. Levy-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors 2005; 23: 183-192.
74. Cazzalini O, Scovassi A, Savio M, Stivala L, Prosperi E. Multiple roles of the cell cycle inhibitor p21 (CDKN1A) in the DNA damage response. Mutat Res 2010; 704: 12-20.
75. Lu S, Liu M, Epner D, Tsai S, Tsai M. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999; 13: 376-384.
76. Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Lavardiere J, Larue H, Lacombe L, Fradet Y. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 2004; 58: 269-276.
77. Gurumurthy S, Rangnekar V. Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem 2004; 91: 504-512.
78. Shrestha-Battarai T, Rangnekar V. Cancer- selective apoptotic effects of extracelular and intracelular Par-4. Oncogene 2010; 29: 3873-3880.
79. Garcia-Cao I, Duran A, Collado M, Carrascosa M, Martin-Caballero J, Flores J, Diaz-Maco M, Moscat J, Serrano M. Tumour-suppression activity of the proapoptotic regulador Par-4. EMBO Rep 2005; 6: 577-583.
80. Qiu G, Ahmed M, Sells S, Mohiuddin M, Weinstein M, Rangnekar V. Mutually exclusive expresión patterns of Bcl-2 and Par-4 in human protate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999; 18: 623-631.
81. Chakraborty M, Qiu S, Vasudevan K, Rangnekar V. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001; 61: 7255-7263.
82. Gao S, Wang H, Lee P, Melamed J, Li C, Zhan F, Wu H, Zhou L, Wang Z. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in prostate gland. J Mol Endocrinol 2006; 36: 463-483.
83. Wada T, Penninger J. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 2838-2849.
84. Aguirre-Ghiso J, Estrada Y, Liu D, Ossowski L.ERK (MAPK) activity as a determinant of tumor growth and dormancia: regulation by P38 (SAPK). Cancer Res 2003; 63: 1684-1695.
85. Engelberg D. Stress-activated protein kinases- tumor supresor or tumor initiator? Semin Cancer Biol 2004; 14:271-282.
86. Maroni P, Koul S, Meacham R, Koul H. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Común Signal 2004; 2: 5-17.
87. Toser A, Yoeli-Lerner M. Akt signaling and cancer: surviving but no moving on. Cancer Res 2006; 66:3963-3966.
88. Liao Y, Grobholz R, Abel U, Trojan L, Michel M, Angel P, Mayer D. Increase of AKT/PKB expresión correlatos with gleason pattern in human prostate cancer. Int J Cancer 2003; 107: 676-680.
89. Jiang B, Li U. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
90. Pfeil K, Eder I, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H. Long-term androgen ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cell. Prostate 2004; 58:259-268.
91. Sasaki T, Nakashiro K, Tanaa H, Azuma K, Goda H, Hara S, Onodera J, Fujimoto I, Tanji N, Yokoyama H, Hamakawa H. Knockdown of AKT isoforms by ARN silencing suppresses the growth of human prostate cáncer cells in vitro and in vivo. Biochem Biophys Res Commun 2010; 399: 79-83.
92. Bunney T, Katan M. Phosphoinositide signaling in cáncer: beyond PI3K and PTEN. Nat Rev Cancer 2010; 10:342-352.
93. Feilotter H, Nagai M, Boag A, Eng C, Mulligan L. Analysis of PTEN and the 10q23 region in primary prostate carcinoma. Oncogene 1998; 16: 1743-1748.
94. Barnes P, Karin M. Nuclear factor-KB- A pivotal transcription factor in chronic inflammatory diseases. The New Engl J Medic 1997; 336: 1066-1071.
95. Balkwill F, Mantovani A. Inflammation and cáncer: back to Wirchow? Lancet 2001; 357: 539-545.
96. Suh J, Rabson A. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100-117.
97. Chen L, Greene W. Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Biol 2004; 5: 392-401.
98. Shukla S, MacLennan G, Fu P, Patel J, Marengo S, Resnick M, Gupta S. Nuclear factor-kappa B/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlatos with disease progresión. Neoplasia 2004; 6: 390-400.
99. Shukla S, Maclennan G, Marengo S, Resnick M, Gupta S Constitutive activation of PI3 K-Akt and NF-kappa B during prostate cancer progresión in autochthonus transgenic Mouse model. Prostate 2005; 64: 224-239.
100. Suh J, Payvandi F, Edelstein L, Amenta P, Zong W, Gelinas C, Rabson A. Mechanisms of constitutive NF-kappa B activation in human prostate cancer cells. Prostate 2002; 52: 183-200.
101. Chen C, Sawyers C. NF-kappa B activates prostate-specific antigen expresión and is upregulated in androgen-indepedent prostate cancer. Mol Cell Biol 2002; 22: 2862-2870.
102. Tang D, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R. Prostate cancer Stem progenitor cell: Identification, characterization and implications. Mol Carcinog 2007; 46: 1-14.
103. Isaacs J. The biology of hormone refractory prostate cancer. Urologic Clinics 1999; 26:263-273.
104. Isaacs J. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-273.
105. Craft N, Chor C, Tran C, Belldegrun A, Dekernion J, Witte O. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59: 5030-5036.
106. Bae K, Su Z, Frye C, Mcclellan S, Allan R, Andrejewski J, Kelley V, Jorgensen M, Steindler D, Vieweg J, Siemann D. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045-2053.
107. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya I, Ichikawa T Fuse H. Neuroendocrine differentiation in the progresión of prostate cancer. Int J Urol 2009; 16:37-44.
108. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in Prostate Cancer. Am J Transi Res 2009; 1: 148-162.
109. Yang J, Ok J, Busby J, Borowsky A, Hung H, Evans C. Aberrant activation of androgen receptor in a new neuropeptideautocrine model of androgen-insensitive prostate cáncer. Cancer Res 2010; 69: 151-161.
110. Bafna S, Kaur S, Batra S. Membranebound mucins: the mechanistic basis for alteration in the growth and survival of cáncer cells. Oncogene 2010; 29: 2893-2904.
111. Kufe D. Mucins in cáncer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
112. Ho S, Niehans G, Lyftogt C, Yan P, Cherwits D, Gum E, Dahiya R, Kim Y. Heterogeneity of mucin gene expresión in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651.
113. Pinder S, McMahon R. Mucins in prostatic carcinoma. Histopatology 1990; 16: 43-46.
114. Legrier M, de Pinieux G, Poirson-Bichat F, Apiou F, Dutrillaux A, Izasen A, Lidereau R, Bara J, Arvelo F, Dutrillaux B, Poupon MF. A new model of human prostate cancer, the PAC 120 xenograft. Pathol Biol 2003; 51: 1-4.
115. Legrier M, de Pinieux G, Boyé K, Arvelo F, Judde J, Fontaine J, Bara J, Poupon MF. Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer 2004; 90: 720-727.
116. Tannock I, Wit R, Berry W, Horta J, Pluzanska A, Chi K. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
117. Mimeault M, Batra S. Recent advances on multiple tumorigenic cascades envolved in prostatic cancer progresión and targeting therapies. Carcinogenesis 2006; 27: 1-22.
118. Figg W, Li H, Sissung T, Ratter A, Wu S, Guilley J, Arlen P, Wright J, Parmes H, Fedenko K, Latham L, Steimbergs S, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustina, docetaxel and thalidomide combination in androgen-indepedent prostate cáncer. BJU Int 2007; 99: 1047-105.
119. Yoo J, Park S, Lee Y. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cáncer cells. J. Cell Biochem 2008; 104: 1636-1646.
120. Djakiew D. Dysregulated expresión of growth factors and their receptors in that development of prostate cancer. Prostate 2000; 42: 150-160.
121. Smith M, Nelson J. Future therapies in hormona-refractory prostate cancer. Urology 2005; 65: 9-16.
122. Talvas J, Caris-Veyrat C, Guy L, Rambeau M, Lyan B, Minet-Quinard R, Lobaccaro J, Vasson M, Georges P, Mazur A, Rock E. Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target gene of cancer prostatic cells. Am J Clin Nutr 2010; 91: 1716-1724.
123. Giovannucci E, Rimm E, Liu Y, Stampfer M, Willett W. A prospective study of tomato products, lycopene and prostate cancer risk. J Natl Cancer Inst 2002; 94: 391-398.
124. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal B. Curcumin dowregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20:7597-7609.
125. Singh H, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006; 6: 259-270.
126. Li M, Zhang Z, Hill D, Wang H, Zhan R. Curcumin a dietary component has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3/ mTOR/ETS2 pathway. Cancer Res 2007; 67: 1988-1996.
127. Li M, Zhang Z, Hill D, Chen X, Wang H, Zhan R. Genistein, a dietary isoflavone down-regulates the MDM2 oncogene at both transcriptional and posttranscriptional levels. Cancer Res 2005; 65: 8200-8208.
128. Park C, Yun H, Lee EB, Min BI, Bae H, Choe W, Kang I, Kim S Ha J. The antioxidant effects of genistein are associated with AMP-activated protein kinase activa-tion and PTEN induction in prostate cáncer cells. J Med Food 2010; 13: 815-820.
129. Kumi-Diaka L, Merchant K, Haces A, Hormann V, Johnson M. Ginestein-selenium combination induces growth arrest in prostate cáncer cells. J Med Food 2010; 13: 842